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Over the last 10 years, there have been important
changes in immunosuppression management and
strategies for solid-organ transplantation, character-
ized by the use of new immunosuppressive agents and
regimens. An organ-by-organ review of OPTN/SRTR
data showed several important trends in immuno-
suppression practice. There is an increasing trend
toward the use of induction therapy with antibod-
ies, which was used for most kidney, pancreas af-
ter kidney (PAK), simultaneous pancreas-kidney (SPK)
and pancreas transplant alone (PTA) recipients in
2004 (72–81%) and for approximately half of all in-
testine, heart and lung recipients. The highest us-
age of the tacrolimus/mycophenolate mofetil combi-
nation as discharge regimen was reported for SPK
(72%) and PAK (64%) recipients. Maintenance of the
original discharge regimen through the first 3 years
following transplantation varied significantly by organ
and drug. The usage of calcineurin inhibitors for main-
tenance therapy was characterized by a clear transi-
tion from cyclosporine to tacrolimus. Corticosteroids
were administered to the majority of patients; how-
ever, steroid-avoidance and steroid-withdrawal proto-
cols have become increasingly common. The percent-
age of patients treated for acute rejection during the
first year following transplantation has continued to
Note on sources: The articles in this report are based on the refer-
ence tables in the 2005 OPTN/SRTR Annual Report, which are not
included in this publication. Many relevant data appear in the fig-
ures and table included here; other tables from the Annual Report
that serve as the basis for this article include the following: Ta-
bles 1.9a and b, 5.6a–i, 6.6a–i, 7.6a–i, 8.6a–i, 9.6a–i, 10.6a–i, 11.6a–
i, 12.6a–i, 13.6a–i, 15.4a and b, 15.5a and b and 15.4–15.15. All of
these tables may be found online at http://www.ustransplant.org.
decline, reaching 13% for those who received a kidney
in 2003, 48% of which cases were treated with anti-
bodies.
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Introduction
This article identifies trends that have evolved over the past
decade in the use of immunosuppression for recipients of
solid-organ transplants. These changes are well captured
by the OPTN/SRTR data. A thorough organ-by-organ re-
view of practices in the use of induction, maintenance and
antirejection medications from 1995 to 2004 is provided.
In addition to the trends in the employment of single im-
munosuppressive drugs, this article details the usage of
combinations of these drugs (regimens) from 1999 to the
present. Moreover, evolving trends in steroid-free immuno-
suppression and immunosuppressive maintenance mini-
mization are described for the same time period. By way
of summary, a final section in the article presents overall
comparisons of immunosuppressive practices across vari-
ous organ groups.
Since they were approved by the FDA in 1994, tacrolimus
(Prograf®, Astellas Pharma US, Deerfield, IL) and the
improved formulation of cyclosporine, the cyclosporine
microemulsion (Neoral®, Novartis, East Hanover, NJ),
and subsequently the generic version of microemulsions
(GengrafTM, Abbott/SangStat, Abbot Park, IL/Fremont, CA),
have provided the foundation for maintenance immuno-
suppression regimens. However, over the last several
years, the use of cyclosporine has been rapidly diminish-
ing, giving way to use of tacrolimus. A similar transition
has also been observed between the antimetabolites aza-
thioprine (Imuran®, GlaxoWellcome (New Zealand) Ltd.,
Auckland, New Zealand) and mycophenolate mofetil
(Cellcept®, Roche, Nutley, NJ), since the latter was
approved by the FDA in 1995. Over the next several
years, a number of new maintenance immunosuppres-
sants were licensed by the FDA: sirolimus (Rapamune®,
Wyeth, Philadelphia, PA, 1999), and the new antibody
preparations, rabbit antithymocyte globulin (Thymoglob-
ulin®, SangStat Medical Corp., Fremont, CA (1999),
daclizumab (Zenapax®, Roche, Nutley, NJ, 1999),
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basiliximab (Simulect®, Novartis, East Hanover, NJ,
2000). While the majority of transplant recipients received
corticosteroids between 1995 and 2002, their use has
somewhat declined during the last two years (2003–
2004), reflecting the belief of some transplant physicians
that some recently introduced immunosuppressive
protocols will allow successful steroid avoidance or
withdrawal.
Over the last several years, tacrolimus/mycophenolate
mofetil has been the most commonly used discharge reg-
imen for solid-organ transplant recipients, with the excep-
tion of intestine and heart recipients. During the same pe-
riod, the combination of tacrolimus/mycophenolate mofetil
was also the most frequently used maintenance regimen
at 1 and 2 years posttransplant for recipients of most
organs.
Antibody-based induction therapy continues to be adminis-
tered to the majority of kidney and pancreas recipients and
to roughly half of intestine and thoracic-organ recipients in
2004. However, its use in liver transplantation has been
noticeably limited. The choice of antibody preparations
employed indicates continuing transition from
muromonab-CD3 (OKT3®, Orthobiotech, Bridgewater,
NJ) and horse antithymocyte globulin (ATGAM®, Phar-
macia & Upjohn, Kalamazoo, MI) to rabbit antithymocyte
globulin (Thymoglobulin®, SangStat Medical Corp.) and the
monoclonal anti-IL-2-receptor antagonists daclizumab and
basiliximab. During the prior 2 years, there has been an
increasing usage of the anti-CD-52 monoclonal antibody
alemtuzumab (Campath-1H®, ILEX Pharmaceuticals, San
Antonio, TX). In 2004, its use ranged from 2% for liver
transplantation to 43% for pancreas transplantation.
Although corticosteroids are prescribed for the majority of
patients, there is an increasing and notable trend toward
steroid avoidance and minimization protocols, particularly
in abdominal organ transplantation. Since 1999 there has
been an increase in steroid withdrawal among first trans-
plant solid-organ recipients. There was also a trend toward
avoiding the use of steroids altogether (steroid avoidance),
as detailed in the organ-specific sections below.
The incidence of acute rejection has declined over the last
10 years, and thus the percentages of patients requiring
antirejection treatment have continued to decline. How-
ever, there has been an increase in the use of antibody
induction for the prophylaxis of acute rejection during the
first year following transplantation. This usage ranged from
18% of heart-lung recipients to 77% of pancreas recipients
in 2004. This has largely reflected the increased utilization
of rabbit antithymocyte globulin.
This article focuses on organ-specific discussions, includ-
ing usage of antibody induction, maintenance immunosup-
pression, corticosteroids and the treatment of acute rejec-
tion. For consistency, we have used generic drug names
wherever possible. However, Table 1 indicates the corre-
sponding drug class names and brand names, which are
commonly employed in clinical practice and many of the
data collection forms used to prepare the tables and fig-
ures of this report.
This article presents a snapshot of current immuno-
suppressive practices for transplantation of all organ
groups. Some procedures are performed less frequently—
particularly intestine, heart-lung and pancreas transplant
alone—and the trends noted for these organ groups may
reflect practices at the smaller number of centers where
such procedures are concentrated.
Unless otherwise noted, the statistics in this article are
drawn from the reference tables in the 2005 OPTN/SRTR
Annual Report. A companion article in this report, ‘Analyti-
cal Methods and Database Design: Implications for Trans-
plant Researchers, 2005,’ explains the methods of data
collection, organization and analysis that serve as the ba-
sis for this article (1). Additional detail on the methods
of analysis employed herein may be found in the ref-
erence tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Kidney Transplantation
Induction immunosuppression for kidney
transplantation
The use of induction immunosuppression for kidney trans-
plantation continued to increase steadily through the
decade (Figure 1). Currently 72% of kidney transplant re-
cipients are receiving induction immunosuppression, com-
pared to 46% in 1995. The administration of antithymocyte
globulin (rabbit), the most commonly used induction agent,
has increased—it is currently used for 37% of patients. In
2003, the first year that the usage for alemtuzumab was re-
ported, it was used for 4% of patients; this practice nearly
doubled in 2004 to 7%.
The overall use of induction therapy was fairly similar
among different racial groups and, surprisingly, among
groups with different panel reactive antibody (PRA) scores.
Across maintenance treatment regimens there was a sig-
nificant fluctuation in the use of induction immunosup-
pression, with nearly 80% of patients on sirolimus/myco-
phenolate mofetil receiving induction treatment, but only
53% of patients on cyclosporine/sirolimus receiving it.
Most of the patients (71%) on steroid-avoidance regimens
between 2000 and 2004 received induction therapy. An-
tithymocyte globulin (rabbit), used for 40% of patients in
steroid-avoidance protocols, was the most frequently used
induction agent also in this group. Alemtuzumab was used
more frequently for patients on steroid avoidance (10%),
compared to other protocols.
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Table 1: Immunosuppressive drug names in OPTN/SRTR data
General class Generic name Brand name
Corticosteroids Prednisone Orasone, Deltasone
Methylprednisolone Solu-Medrol, A-methaPred, Medrol
Dexamethasone Decadron
Calcineurin inhibitors Tacrolimus (or FK-506) Prograf
Cyclosporine (also cyclosporin A, CsA) Sandimmune, Neoral; manufacturers of generic
cyclosporine include SangStat (SangCya)1,
Abbott (Gengraf), Apotex, Bedford Eon Labs,
Geneva, Ivax Pharms, Novex, Morton Grove,
and Pliva
Antimetabolites Azathioprine (or AZA) Imuran
Cyclophosphamide Cytoxan, Neosar
Mycophenolate mofetil (also MMF,
RS61443)
CellCept




Leflunomide (or LFL)2 Arava
Polyclonal antibodies Antithymocyte globulin (rabbit) Thymoglobulin




Anti-CD3 monoclonal antibodies Muromonab-CD3 Orthoclone OKT3
Anti-CD52 monoclonal antibodies Alemtuzumab2 Campath-1H
Anti-IL-2 receptor monoclonal antibodies Basiliximab Simulect
Daclizumab Zenapax
TOR inhibitors Sirolimus (or rapamycin) Rapamune
Everolimus (or RAD0001)3 Certican (Phase III Trial)
Other FTY7203 (Phase III Trial)
Note: For some immunosuppressants, the original data collection forms list brand names instead of generic names. As in the SRTR
database, the figures in this article follow the terms on the data collection forms. However, the text refers to the drugs by their generic
names when no additional generic alternatives exist.
1Currently withdrawn from the market.
2Off label use.
























Source: 2005 OPTN/SRTR Annual Report, Table 5.6a.
Figure 1: Immunosuppression agents used for induction in
kidney transplantation, 1995–2004.
Maintenance immunosuppression before discharge
for kidney transplantation
Calcineurin inhibitors were still the cornerstone of immuno-
suppression in kidney transplantation in 2004—93% of pa-
tients received them as part of their discharge regimen
(Figure 2). Tacrolimus is the calcineurin inhibitor of choice
and its use continues to grow, with 72% of patients
treated with tacrolimus at discharge versus only 21%
with cyclosporine. The use of mycophenolate mofetil,
the most frequently used antiproliferative agent, is also
still increasing, with 81% of patients discharged on my-
cophenolate mofetil. Since a peak of 17% in 2001, the
use of sirolimus (rapamycin) has declined. In 2004, only
12% of patients were discharged on regimens containing
sirolimus.
Use of the combination of tacrolimus/mycophenolate
mofetil continues to increase; it is the most fre-
quently used discharge regimen (60%), followed by
cyclosporine/mycophenolate mofetil, the use of which
has continued to decline, reaching 16% in 2004
(Figure 3). Employment of the third most frequent regimen,
tacrolimus/sirolimus, declined slightly to 5% in 2004. The
use of the cyclosporine/sirolimus combination has contin-
ued to decline, with only 3% of patients being discharged
on it in 2004. Use of the sirolimus/mycophenolate mofetil
combination has remained under 1%.
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Figure 2: Trends in maintenance im-
munosuppression prior to discharge





















Source: 2005 OPTN/SRTR Annual Report, Table 5.6d.
Figure 3: Trends in discharge im-
munosuppression regimens for kid-
ney transplantation, 1995–2004.
Maintenance immunosuppression 1 and 2 years
following kidney transplantation
Tacrolimus/mycophenolate mofetil is also the most fre-
quently used maintenance immunosuppression com-
bination at 1 and 2 years following transplantation,
and its prevalence for maintenance use has increased
in recent years. At 1 year after transplantation in
2003, 51% of patients were receiving tacrolimus/
mycophenolate mofetil, 17% were receiving cyclosporine/
mycophenolate mofetil, 8% tacrolimus/sirolimus and
1% sirolimus/mycophenolate mofetil (Figure 4). Both
the tacrolimus/sirolimus and the sirolimus/mycophenolate
mofetil regimens were more prevalent at 1 and 2 years
after transplant than at discharge, indicating a significant
switch toward these combinations after transplant. Sur-
prisingly, at 1 year about 7% and at 2 years about 2%
of patients were receiving tacrolimus alone, compared to
about 4% at discharge. All of these percentages refer to
medication regimens regardless of steroids, meaning that
most of the patients were on steroids in addition to the
indicated regimens.
A minority of patients received only one drug for mainte-
nance immunosuppression, but there has been an increase
in patients on strict monotherapy at hospital discharge from
2% in 1999 to 4% in 2004 (SRTR analysis, May 2005). Most
of these patients are either on steroids or on tacrolimus
alone. The picture is similar at a year after transplant, with
a small but steadily increasing number of patients on only
one drug (3% in 2003) and more than half of these receiv-
ing only tacrolimus.
Steroid withdrawal and steroid avoidance
for kidney transplantation
As seen in Figure 5, steroid withdrawal became increas-
ingly established among recipients of a first kidney trans-
plant between 1999 and 2003. In 1999, 4% of patients
were taken off steroids by 1 year following transplantation,
compared to 10% in 2003. At 2 years, a slightly higher
proportion of patients who had been on steroids at dis-
charge were no longer receiving them. Steroid withdrawal
was slightly more common among living versus deceased
donor transplants.




















Source: 2005 OPTN/SRTR Annual Report, Table 5.6f.
Figure 4: Trends in immunosuppression maintenance regi-
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Source: 2005 OPTN/SRTR Annual Report, Tables 15.4a.2 and 15.4b.2.
Figure 5: Steroid-withdrawal rates at 1 year posttransplant
for deceased donor and living donor kidney transplants, 1999–
2003.
Currently, steroid avoidance is much more prevalent than
steroid withdrawal, with 23% of all first transplants in 2004
discharged without steroids (Figure 6). The first signifi-
cant numbers of steroid-avoidance protocols were seen
in 2000, when 5% of patients were discharged with-
out steroids; there has since been a steady increase in
the prevalence of steroid-free regimens. Steroid-avoidance
protocols are used more frequently for living donor trans-
plant recipients (28% in 2004) than for recipients of de-
ceased donor organs (20%).
Maintenance regimen change and discontinuation
for kidney transplantation
A surprisingly low percentage of patients continued their
original immunosuppressive discharge regimen through-
out the first 3 years following transplantation, as seen in
Figure 7. Already at a year, a substantial number of patients
were reported not to be on their original regimen. There
was significant variability by immunosuppressive regimen.
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Source: 2005 OPTN/SRTR Annual Report, Tables 15.4a.1 and 15.4b.1.
Figure 6: Steroid-avoidance rates for deceased donor and liv-
















At Discharge 1 Year Post-Transplant
2 Years Post-Transplant 3  Years Post-Transplant
Source: 2005 OPTN/SRTR Annual Report, Table 5.6h.
Figure 7: Percentage of kidney transplant patients still on
original discharge regimens at 1, 2 and 3 years posttransplant,
for the five most common regimens in 2001.
their original tacrolimus/mycophenolate mofetil discharge
therapy at both 1 (75%) and 3 years (57%) following trans-
plantation. All sirolimus-based regimens showed high regi-
men change rates, particularly by 3 years after transplanta-
tion, with up to 65% of patients not on the original regimen
in the sirolimus/mycophenolate mofetil group in 2001.
Antirejection treatment for kidney transplantation
The percentage of patients treated for acute rejection has
continued to decrease. Only 13% of all patients who re-
ceived a kidney in 2003 were reported to have been treated
for acute rejection during the first year following transplan-
tation (Figure 8). Among these acute rejection episodes,
treatment with antibodies has increased—in 2003, 48%
of patients requiring antirejection treatment received anti-
bodies. The rise in antibody treatment largely reflects the
increased use of antithymocyte globulin (rabbit) for antire-
jection (31% of antirejection treatments in 2003, up from
24% in 2002). Corticosteroids remain a principal element of
rejection treatment even though their use declined slightly.
In 2003, 72% of patients requiring antirejection treatment
received steroids, down from 80% the previous year.
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Total Transplants Treated w ith Antirejection Drugs (Left
Scale)
Thymoglobulin Used an an Antirejection Treatment (Right
Scale)
Figure 8: Percentage of kidney transplants with antirejection
treatments and thymoglobulin used as an antirejection treat-
ment by year, 1994–2003.
Pancreas Transplantation
Immunosuppressive practices and trends after pancreas
transplants, in contrast to other solid-organ transplants,
vary with the different recipient categories. It is well docu-
mented that pancreas allograft rejection rates are highest in
nonuremic recipients of a pancreas transplant alone (PTA),
next highest in posturemic recipients of a pancreas after
kidney transplant (PAK) and lowest in uremic recipients
of a simultaneous pancreas and kidney (SPK) (2,3). As a
consequence, induction and maintenance regimens differ
between the three recipient categories—comparisons are
usually made between solitary pancreas transplants (PTA
and PAK categories) versus combined pancreas and kidney
transplants (SPK category). As shown in this analysis, im-
munosuppressive therapy after pancreas transplants con-
tinues to evolve; there appears to be a primary trend toward
steroid avoidance, but avoidance of calcineurin inhibitors is
also practiced.
Induction immunosuppression for pancreas
transplantation
The use of antibody induction therapy remains higher for
pancreas recipients than for recipients of any other solid
organ; in 2004, the rate of such use reached over 80% in
all three recipient categories. This rate is higher than it was
5 years ago, when 63% (PTA) to 67% (PAK) of pancreas
recipients were given induction therapy.
Over the last 2–4 years, the most commonly used anti-
body administered after pancreas transplantation was
antithymocyte globulin (rabbit), accounting for about half
of all antibodies given for pancreas transplant induction
therapy (Figure 9). Since 2003, the use of the monoclonal
anti-CD-52-directed antibody alemtuzumab has been gain-
ing acceptance; in 2004, it was the second most preva-
lent among all the three recipient categories. Alemtuzumab
was given to 43% of PTA recipients (vs. 19% of SPK and























Source: 2005 OPTN/SRTR Annual Report, Table 8.6a.
Figure 9: Immunosuppression agents used for induction in
simultaneous kidney-pancreas transplantation, 1995–2004.
are the third most commonly used group, with basiliximab
more common for SPK recipients and daclizumab more
common for solitary pancreas transplant recipients during
the last 5 years. Over time, the use of muromonab-CD3
and horse antithymocyte globulin/antilymphocyte globulin
preparations has sharply decreased. They are now each
used less than 3% of the time.
Another trend in induction therapy was noted in the 2005
report of the International Pancreas Transplant Registry
(IPTR): Depleting and nondepleting agents are increasingly
combined for induction therapy, least frequently for SPK
recipients and most frequently for PTA recipients (2,3).
The 2005 IPTR report also showed that graft survival in all
the three recipient categories was higher when antibodies
(vs. no antibodies) were used. Furthermore, for SPK re-
cipients, the use of nondepleting antibodies, either alone
or in combination, seems to be superior, when compared
to the use of depleting antibodies alone or no induction
therapy at all. For PAK recipients, graft survival rates were
higher in those given depleting antibodies, either alone or in
combination; for PTA recipients, no such differences were
noted.
Of note, most recipients who received antithymocyte glob-
ulin (rabbit) or anti-CD-25 antibodies for induction ther-
apy were placed on tacrolimus/mycophenolate mofetil
maintenance therapy; in contrast, a higher percent-
age of patients on alemtuzumab for induction ther-
apy were treated with either tacrolimus monotherapy
or on sirolimus/mycophenolate mofetil for maintenance
therapy.
Maintenance immunosuppression before discharge
for pancreas transplantation
In essence, four basic trends in maintenance immunosup-
pression during the initial transplant hospitalization have
been defined over time.
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Figure 10: Trends in maintenance immunosuppression prior
to discharge for simultaneous kidney-pancreas transplanta-
tion, 1995–2004.
(i) The use of steroids for maintenance immunosuppres-
sion has slowly but steadily decreased. In 2004, almost
24% of SPK recipients and almost 50% of PTA re-
cipients were not given steroids (SRTR analysis, May
2005). Avoiding steroids appears to have become a
major focus because of their deleterious side effects,
particularly for patients with a long-standing history of
diabetes mellitus.
(ii) Among calcineurin inhibitors, tacrolimus remains the
dominant agent (Figure 10). Since 2000, usage rates
have been well over 80% in all three recipient cate-
gories. However, in 2004, though only among those un-
dergoing PTA, a lower percentage of recipients (74%)
were placed on tacrolimus. The use of cyclosporine
and its different formulas has been marginalized. Its
rate of use now ranges from 1% (PTA) to 9% (PAK).
(iii) The antimetabolite of choice clearly is mycopheno-
late mofetil. In 2003 and 2004, 80–85% of all SPK
and PAK recipients and 63–71% of all PTA recipients
were placed on mycophenolate mofetil. Since 1999,
fewer than 4% of recipients in all three categories were
placed on azathioprine; in 2003 and 2004, fewer than
2% were.
(iv) Since 2001, the use of rapamycin has remained fairly
constant, ranging from 11% (in 2001 for PTA) to 22%
(in 2001 for PAK).
Regarding combination therapy during the initial trans-
plant hospitalization, the combination of tacrolimus and
mycophenolate mofetil has been most common, account-
ing for 60–70% of all treatment regimens since 1999 for
SPK and PAK recipients. Only in the PTA category, since
2001, have fewer than 60% of recipients been placed
on tacrolimus/mycophenolate mofetil; in contrast, the per-
centage of tacrolimus monotherapy was highest for PTA
recipients (10% in 2004). The second most frequently used
combination in 2003 and 2004 was tacrolimus/rapamycin,
accounting for 4–15% of protocols in each of the three
recipient categories. Since 2001, cyclosporine-based com-
bination therapy (with mycophenolate mofetil, azathioprine
or sirolimus) has been used in fewer than 10% of all regi-
mens in all the three categories.
Calcineurin inhibitor-free protocols during the initial trans-
plant hospitalization remain uncommon. The use of ra-
pamycin/mycophenolate mofetil increased only in the PAK
and SPK categories in 2003 and 2004, accounting for 2–
7% of all combination regimens; its rate of use in the
PTA category was less than 1%. Interestingly, in the PTA
and PAK categories, the use of other protocols—such as
the calcineurin inhibitor- and steroid-free alemtuzumab-
mycophenolate mofetil-based protocol used at the Uni-
versity of Minnesota (4)—has increased; in 2004, these
‘other’ protocols accounted for 22% of therapy in the PTA
category, 10% in the PAK category and 9% in the SPK
category.
Maintenance immunosuppression 1 and 2 years
following pancreas transplantation
The trends in maintenance immunosuppression within
the first year following transplantation have been similar
to the trends during the initial transplant hospitalization
(Figure 11):
(i) Attempts at steroid avoidance began in 2003, when
about 20% of SPK and PAK recipients and about 40%
of PTA recipients were receiving steroid-free regimens.
These numbers are slightly lower than during the initial
transplant hospitalization, indicating that some recipi-
ents were administered steroids later on.
(ii) Beginning in the mid-1990s, tacrolimus has been the
most common calcineurin inhibitor, even at the first
year following transplantation. In 2003, 74% (PTA),
76% (PAK) and 82% (SPK) of recipients were main-
tained on tacrolimus at 1 year following transplantation;
the percentage of cyclosporine-based maintenance























Source: 2005 OPTN/SRTR Annual Report, Table 8.6g.
Figure 11: Immunosuppression agents used for maintenance
between discharge and 1 year posttransplant in simultaneous
kidney-pancreas transplantation, 1994–2003.





















Source: 2005 OPTN/SRTR Annual Report, Table 8.6f.
Figure 12: Trends in immunosuppression maintenance reg-
imens, 1 year posttransplant for simultaneous kidney-
pancreas transplantation, 1999–2003.
SPK, 8% for PAK recipients and 8% for PTA recipients
(Figure 12).
(iii) Among antimetabolites, mycophenolate mofetil is
most commonly used for maintenance. In 2002 and
2003, about 80% of PAK and SPK recipients were re-
ceiving mycophenolate mofetil at 1 year after trans-
plantation; only for PTA recipients was the percentage
lower (59% in 2003). Since 2001, ≤3% of the recipi-
ents in all the three categories were given azathioprine.
(iv) The use of rapamycin appears to have increased within
the first year following transplantation (vs. the initial
transplant hospitalization). In 2002 and 2003, 25–32%
of all recipients were receiving rapamycin, about 10%
more than during the initial transplant hospitalization.
This trend toward greater usage of rapamycin after the
transplantation may be explained by concern over a
higher incidence of rapamycin-associated wound com-
plications immediately following transplantation.
The most common combination therapy for the first
year in all the three recipient categories is now
tacrolimus/mycophenolate mofetil. Since 2000, it was
given to 55–60% of SPK and PAK recipients. Only in
the PTA category was a decrease in this combina-
tion’s use noted, in both 2002 (48%) and 2003 (30%).
The second most common combination protocol was
tacrolimus/rapamycin, given to 15–20% of all recipients in
2002 and 2003. Only in PTA categories was the adminis-
tration of ‘other’ protocols prominent (18% PTA) in 2002
and 2003. This finding may also reflect the increased use
of alemtuzumab/mycophenolate mofetil-based protocols
that are free of both calcineurin inhibitors and steroids.
Since 1999, cyclosporine-based immunosuppression
has accounted for less than 10% of maintenance ther-
apy (highest in the SPK category). In 2003, tacrolimus
monotherapy was used for 2–3% of SPK and PAK recip-
ients and up to 17% of PTA recipients. The calcineurin
inhibitor-free rapamycin/mycophenolate mofetil proto-
col saw a slight increase in 2003 (2% SPK, 1% PAK
and PTA). Over time, the use of tacrolimus/rapamycin
(vs. tacrolimus/mycophenolate mofetil) increased.
In the second year following transplantation, about
17–20% of recipients in all the three categories re-
ceived tacrolimus/rapamycin (vs. 55% on tacrolimus/
mycophenolate mofetil). This change may reflect
tacrolimus/mycophenolate mofetil-associated gastroin-
testinal problems. In the second year following transplanta-
tion, ≤2% of all protocols were rapamycin/mycophenolate
mofetil (calcineurin inhibitor-free).
Outcome by maintenance regimen in pancreas
transplantation
According to the 2005 IPTR report, the 1-year pancreas
graft survival rates for 2000–2004, for recipients of primary
deceased donor pancreas transplants who were given
anti-T-cell induction therapy and tacrolimus/mycophenolate
mofetil for maintenance therapy, were as follows: 88% for
SPK recipients, 83% for PAK recipients and 80% for PTA
recipients. If tacrolimus/rapamycin was instead used for
maintenance therapy, the rates were as follows: 87% for
SPK recipients and 83% for both PAK and PTA recipients.
The outcomes with either of these two maintenance pro-
tocols were similar. Multivariate models showed a highly
significant reduction in early and late pancreas graft fail-
ure rates with tacrolimus-mycophenolate mofetil. Indepen-
dently, the use of rapamycin decreased the hazard ratios
for pancreas graft failure (3).
Maintenance regimen change and discontinuation
for pancreas transplantation
A relatively low percentage of recipients in all three cat-
egories continued on their original immunosuppressive
discharge protocol throughout their first 3 years follow-
ing transplantation. The highest rate of regimen change
occurred within the first year, but modifications contin-
ued throughout the second and third year. Figure 13
shows the rates of discontinuation for the three reg-
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Source: 2005 OPTN/SRTR Annual Report, Table 8.6h.
Figure 13: Percentage of simultaneous kidney-pancreas
transplant patients still on original discharge regimen at 1, 2
and 3 years posttransplant, for the three most common regi-
mens in 2001.


























Source: SRTR analysis, May 2005.
Figure 14: Total steroid-avoidance rates at discharge for si-
multaneous kidney-pancreas transplants, 1995–2004.
recipients in the three categories who were initially
placed on a regimen of tacrolimus/mycophenolate mofetil
(the most common protocol) in 2001, only about 40–
60% remained on it 3 years later. Of all recipients on
tacrolimus/rapamycin, only 33% (PTA) remained on it
3 years later. Of note, the relatively small fraction of re-
cipients on rapamycin/mycophenolate mofetil (calcineurin
inhibitor-free) at the time of their initial transplant hospital-
ization was similar to that seen 3 years later.
Steroid withdrawal and steroid avoidance
for pancreas transplantation
Rates of steroid withdrawal and steroid avoidance
(Figure 14) following pancreas transplantation have both
been rising since 1999. In 2004 (vs. 2000), 49% (vs. 17%)
of PTA recipients and 24% (vs. 3%) of SPK recipients were
on a steroid-avoidance regimen. The steroid-withdrawal
rates at 1 and 2 years following transplantation have re-
mained stable (at about 10%) for SPK recipients; this rate
represents a clear increase from 1998 (<3%). For PTA re-
cipients, in 2003 and 2004, the steroid-withdrawal rates
were only slightly higher than those of SPK recipients. In
general, steroid avoidance has been more popular than
steroid withdrawal for pancreas recipients.
Regarding induction therapy, steroid-avoidance protocols
were more commonly used if patients were given antithy-
mocyte globulin (rabbit) or alemtuzumab for induction, and
least commonly if they were given anti-CD-25 antibodies
or no antibodies at all.
Minimization of immunosuppression (one-drug
regimens) for pancreas transplantation
In general, minimization of immunosuppression to only one
drug for maintenance has been infrequent among SPK re-
cipients, but more common for PAK and PTA recipients.
Since 1998, the percentage of SPK recipients receiving
only one drug at the time of their hospital discharge and
within the first 3 years following transplantation ranged
from 0.4% to 6.4%; the most commonly used drug for
monotherapy in 2004 was tacrolimus (≥50%), followed by
mycophenolate mofetil and rapamycin (SRTR analysis, May
2005).
Up to 11% of PAK recipients were on only one drug at
discharge, but the percentage decreased within the first
2 years posttransplant (down to 4%), only to increase
again in the third posttransplant year (up to 12%). For
PAK recipients, mycophenolate mofetil was the most com-
monly used drug for monotherapy (SRTR analysis, May
2005).
For PTA recipients, an increase in monotherapy during the
initial transplant hospitalization was noted between 2000
(15%) and 2004 (33%) (SRTR analysis, May 2005). Over
time, monotherapy was not sustained, and by the third
year, no more than 6% remained on monotherapy. My-
cophenolate mofetil was the most commonly used drug
for monotherapy during the initial transplant hospitaliza-
tion and in the third year following transplantation, but
tacrolimus was the most commonly used drug in the first
and second year.
Antirejection treatment for pancreas transplantation
Antibodies are used for antirejection treatment more fre-
quently for pancreas recipients than for recipients of any
other solid organ. In 2002 and 2003, more than 50% of
all pancreas recipients requiring antirejection treatment
were placed on antibodies. Since 1999, the rates of an-
tibody use for antirejection treatment have been highest
for PTA recipients (up to 90% in 2000) and lowest for
SPK recipients (as low as 32% in 2001). The most com-
monly used antibody for antirejection treatment since 2001
has been antithymocyte globulin (rabbit), followed by
muromonab-CD3, which was the most commonly used
antirejection antibody from 1994 through 2000 (Figure 15).
Alemtuzumab has emerged as another potent antirejec-
tion agent, particularly after solitary pancreas transplants.
In 2003, for PTA and PAK recipients, alemtuzumab was al-
ready the second most commonly used antibody. Anti-IL-2
receptor monoclonal antibodies (basiliximab, daclizumab)
accounted for about 10% of all antirejection treatments in
2003.
Steroids remain another cornerstone of antirejection treat-
ment, given in about 80% of all rejection episodes. Their
use is highest for PTA recipients (as high as 90% in 2001).
In 2003, only 70% of SPK and PAK recipients with rejec-
tion were given steroid treatment. It remains to be seen
whether steroids will be used less frequently when, for ex-
ample, alemtuzumab is administered for antirejection treat-
ment.
In general, the number of rejection episodes has declined
since the late 1990s, presumably because of the introduc-
tion of both tacrolimus and mycophenolate mofetil in the
mid-1990s. More efficient maintenance immunosuppres-
sion has lessened the need for antirejection treatment.















































Source: 2005OPTN/SRTR Annual Report, Table 8.6i.
Figure 15: Trends in antibody thera-




















Source: 2005 OPTN/SRTR Annual Report, Table 9.6a.
Figure 16: Trends in induction immunosuppression for liver
transplantation, 1995–2004.
Liver Transplantation
Induction immunosuppression for liver
transplantation
In contrast to all other solid-organ transplantation, the use
of induction antibody preparations in liver transplantation
remains relatively uncommon. As shown in Figure 16, the
overall use of induction immunosuppression for liver re-
cipients during 2003 and 2004 was 21%; the rate has in-
creased steadily since 1997, when it was 7%. This rise in
induction has been ascribed to an increase in calcineurin in-
hibitor avoidance in the early posttransplant period to avoid
aggravation of renal dysfunction (a response to the higher
prevalence of high MELD score patients with renal dys-
function), and to increased use associated with protocols
to reduce early corticosteroid use (5), as well as to achieve
early calcineurin inhibitor monotherapy (6).
The trend of induction antibody selection continues to favor
the class of anti-IL-2 receptor alpha chain monoclonal anti-
bodies (basiliximab and daclizumab), which make up a total
of 11% overall use. Within this class, basiliximab use (6%
overall) is slightly more common than is daclizumab (5%
overall). The use of rabbit antithymocyte globulin for induc-
tion was 7% of all liver transplant recipients. The long-term
impact of alemtuzumab for liver recipients has not been
defined and the FDA has not approved its use for organ
transplantation; nevertheless, alemtuzumab was used in
2% of all induction following liver transplantation in 2004,
twice what it was the previous year (7).
Maintenance immunosuppression before
discharge for liver transplantation
The use of maintenance immunosuppression continues to
favor the use of therapy based on calcineurin inhibitors.
With the length of hospital stays after liver transplanta-
tion gradually falling to 8–15 days (8), and the impact
of induction antibody use with delayed initiation of cal-
cineurin inhibitors, the correlation of maintenance immuno-
suppressive therapy at the time of discharge with long-
term outcomes has become increasingly difficult to de-
termine. Nevertheless, the use of calcineurin inhibitors
was reported in 97% of patients discharged from the hos-
pital after liver transplantation in 2003–2004, as seen in
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Figure 17: Trends in maintenance immunosuppression prior
to discharge for liver transplantation, 1995–2004.
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Immunosuppression, 1994–2004
largest proportion of calcineurin inhibitor use (89% of re-
cipients) compared to all the cyclosporine preparations (8%
of recipients). Use of antimetabolite therapy (mycopheno-
late mofetil or azathioprine) at the time of discharge was
reported for 58% of all liver transplant recipients, and a
recent study has suggested that the combination of my-
cophenolate mofetil and a calcineurin inhibitor may im-
prove long-term outcomes, as compared to a calcineurin
inhibitor alone (9). Sirolimus use at the time of discharge
was noted for only 5% of liver transplants in 2003 and
2004.
Corticosteroid avoidance was stable at 5–8% until 1999,
with the rates increasing to 20% in 2004. Avoiding corti-
costeroids has been postulated to be beneficial in reduc-
ing the impact of hepatitis C virus (HCV) recurrence in liver
transplantation. However, analysis of steroid avoidance by
listing diagnosis revealed that the increase in steroid avoid-
ance was similar between the HCV-positive and -negative
liver transplant recipients.
It has also been proposed that mycophenolate mofetil use
for liver recipients transplanted for HCV may diminish HCV
recurrence, due to its potent effects against other fla-
viviruses in vitro (10), although clinical studies have not
consistently confirmed this (11). The use of mycophe-
nolate mofetil has gradually increased since its introduc-
tion in 1995. Currently, a slightly larger number of HCV-
positive patients receive mycophenolate mofetil than do
HCV-negative patients (59% HCV+ vs. 55% HCV−) (SRTR
analysis, May 2005). Confirmation of whether the prac-
tice of steroid avoidance and mycophenolate mofetil use
in HCV patients is truly associated with improved clinical
outcomes is pending the results of ongoing clinical trials
examining the long-term outcomes of this approach (12).
Maintenance immunosuppression 1 and 2 years
following liver transplantation
The pattern of immunosuppressive drug use changes in
the years following liver transplantation. Withdrawal or
elimination of corticosteroids early in the posttransplant
period has been suggested as a means to avoid ad-
verse effects related to corticosteroid use. Thus, the long-
term steroid-free regimens have been widely touted; the
OPTN/SRTR data reveal that corticosteroid administration
indeed decreases over time. Of the approximately 80% of
deceased donor liver transplant recipients discharged on
corticosteroids, only 49% are still using them by the end
of the first year after transplantation and 33% 2 years after
transplantation.
Calcineurin inhibition is still the most prevalent baseline
immunosuppression at 1 year after transplantation, when
93% of liver recipients are receiving a calcineurin inhibitor,
with 84% tacrolimus and 9% cyclosporine. Cyclosporine
antimetabolite use decreases at 1 year following transplan-
tation (55%, compared to 58% at the time of discharge),
again with mycophenolate mofetil being the predominant
agent (52%, vs. 3% for azathioprine). This decreased use
of mycophenolate mofetil from the time of discharge to the
1 year posttransplant mark is consistent with single-center
reports that report intolerance (13) or unknown long-term
cost-benefit assessment (14). Sirolimus administration is
12% at 1 year posttransplant, reflecting a greater level of
confidence in its use after the early posttransplant period,
when the risk of thrombosis and wound complications are
diminished and the risk of nephrotoxicity increases (15).
Minimization of immunosuppression (one-drug
regimens) for liver transplantation
Monotherapy immunosuppression has grown from 4% of
patients at the time of hospital discharge in 2000 to 12%
in 2004, the vast majority (>80%) being on tacrolimus
alone (SRTR analysis, May 2005). However, most prac-
tices attempting to achieve monotherapy immunosuppres-
sion, usually with a calcineurin inhibitor, select patients
with stable graft function and frequently wean them from
adjunctive immunosuppressants 6–12 months following
transplantation. The OPTN/SRTR data reveal that at 1 year
following transplantation, the proportion of recipients on
monotherapy has increased to 34%, with 87% of these
patients on tacrolimus alone, 6% on cyclosporine, 4% on
sirolimus and <1% on mycophenolate mofetil. By 2 years,
monotherapy is used for 46% of recipients, with 86% on
tacrolimus alone, 7% on cyclosporine, 6% on sirolimus and
1% on mycophenolate mofetil. By 3 years following trans-
plantation, 50% of liver recipients have achieved monother-
apy status, with 85% on tacrolimus, 8% on cyclosporine,
5% on sirolimus and <1% on mycophenolate mofetil.
Antirejection treatment for liver transplantation
The incidence of acute rejection continues to decline from
already low levels—in 2003, 18% of liver transplant re-
cipients were reported to have experienced a rejection
episode, a decrease from 24% the prior year. As noted
previously, this decrease likely reflects both improved po-
tency of immunosuppressive regimens and improved abil-
ity to distinguish between recurrent HCV and acute rejec-
tion (16).
Treatment of rejection continues to be primarily
corticosteroid-based, with the vast majority of rejec-
tions being reversed with a short course or bolus of
corticosteroids. Ninety-two percent of rejections were
reversed by this approach or augmented baseline immuno-
suppression, while 18% were considered steroid-resistant
and required antibody therapy. Within this group of an-
tibody treatment of rejection, 5% of patients received
an anti-CD3 monoclonal antibody, 7% an antithymo-
cyte/lymphocyte globulin, 2% alemtuzumab and 4% an
anti-IL-2 receptor antibody. Compared to previous years,
this predominant use of the polyclonal antibodies is new
(Figure 18).






















Source: 2005 OPTN/SRTR Annual Report, Table 9.6i.
Figure 18: Percentage of OKT3 and thymoglobulin used in
antirejection treatments, for liver transplants by year, 1994–
2003.
Intestine Transplantation
The number of intestine transplants performed in the
United States continues to increase but is still relatively
small compared with other organs. In 1995, only 43 cases
with data on immunosuppression were registered with the
SRTR; this number increased to 148 in 2004. The interpre-
tation of any trends in immunosuppression use is limited
by the small total number of cases.
Induction immunosuppression for intestine
transplantation
The use of induction therapy in intestine transplantation
decreased to 50% in 2004, compared to 74% in 2003 and
57% in 2002. Alemtuzumab, rabbit antithymocyte globulin
and daclizumab accounted for 92% of induction therapy
(Figure 19). The use of alemtuzumab increased from 9% in
2003 to 19% in 2004, becoming the most commonly used
induction agent in intestine transplantation. Over the year,
alemtuzumab’s use for induction replaced much of the use
of rabbit antithymocyte globulin (down to 18% from 46%)






















Source: 2005 OPTN/SRTR Annual Report, Table 10.6a.
Figure 19: Trends in induction immunosuppression for intes-
tine transplantation, 1995–2004.
Maintenance immunosuppression before
discharge for intestine transplantation
Over the last decade, the overwhelming majority of in-
testine recipients have been maintained on tacrolimus,
whose usage reached 98% in 2004. A very small percent-
age of intestine recipients received cyclosporine; 6% in
1995, 2% in 1997 and 8% in 1998. Although both aza-
thioprine and mycophenolate mofetil were used between
1995 and 2001, the latter was the only antimetabolite used
since, and it was prescribed for only 9% of patients in
2003 and 2004. Sirolimus was used for 12% of mainte-
nance immunosuppression in 2004. From 2000 to 2004,
tacrolimus/sirolimus was the most commonly used dis-
charge regimen for intestine transplantation (15%), not
the case for most other types of transplantation. The sec-
ond most common discharge regimen during this period
was tacrolimus/mycophenolate mofetil, which was admin-
istered to 8% of patients. As was the case for other solid
organs, there has been an increasing trend toward imple-
menting steroid-avoidance protocols; in 2004, 27% of pa-
tients were not administered steroids, compared to 7%
and 4% in 1995 and 2000, respectively (SRTR analysis,
May 2005).
Maintenance immunosuppression 1 and 2 years
following intestine transplantation
In 2003, only 87 intestine recipients (75%) had immuno-
suppression information reported at the end of the first
year following transplantation. Almost all intestine recipi-
ents are maintained on tacrolimus. The use of cyclosporine
has diminished, reaching 1% in 2002 and 0% since. An-
timetabolites were used for 9% of patients with mycophe-
nolate mofetil, the only prescribed antimetabolite in 2003
(9%). As was the case at discharge, sirolimus was the
only TOR inhibitor used (16% in 2003). Tacrolimus alone or
with steroids has been the most commonly used regimen
1 year and 1 years following intestine transplantation. In
general, a very low percentage of intestine recipients con-
tinued using the discharge regimens tacrolimus/rapamycin
or tacrolimus/mycophenolate mofetil by 2 years after trans-
plantation. There has been a general trend toward increas-
ing steroid-withdrawal rate at 1 year among first intestine
recipients, reaching a maximum of 29% in 2003 (SRTR
analysis, May 2005).
Antirejection treatment for intestine transplantation
Over the last decade, there has been an overall decrease in
the incidence of graft rejection requiring treatment during
the first year following intestine transplantation. In 1997,
the incidence of graft rejection was 68%, which decreased
to 37% in 2001, 45% in 2002 and 56% in 2003. This decline
is associated with the use of modified induction therapy
agents, particularly daclizumab, which was not used before
1998 (Figure 20). In 2003, corticosteroids were the most
commonly used agent to treat rejection (92%), followed
by antibodies (39%). Muromonab-CD3 continued to be the














































Source: 2005 OPTN/SRTR Annual Report, Table 10.6i.
Figure 20: Trends in antibody ther-
apy for rejection episodes in first year
following intestine transplantation,
1994–2003.
most commonly administered antibody therapy in intestine
transplantation (28%), followed by alemtuzumab (15%, up
from 8% in 2002) and rabbit antithymocyte globulin (3%).
Heart Transplantation
Induction immunosuppression for heart
transplantation
The use of an induction regimen in heart transplant recip-
ients, and the various types of agents utilized, has grad-
ually changed over the last decade. While the frequency
of the administration of these agents remains far below
that seen currently in kidney transplantation, and below
the rates seen in heart transplantation during the late 1980s
and early 1990s, there has been a gradual increase in their
use in the past 6 years. Figure 21 shows the changing pat-
terns for induction therapy from 1995 through 2004.
During the past decade, there was a decline in the percent-
age of recipients receiving an induction agent to a low of

















Source: 2005 OPTN/SRTR Annual Report, Table 11.6a.
Figure 21: Trends in induction immunosuppression for heart
transplantation, 1995–2004.
and 2004. Center-specific practice patterns, combined with
recipient comorbidities (renal dysfunction or a high risk for
rejection), have often been cited as the primary influences
on the use and choice of specific agents. Muromonab-
CD3 and antithymocyte globulin (equine) were the most
commonly used perioperative induction agents until 2000.
Seventeen percent of patients received antithymocyte
globulin (equine) in 1995, compared to only 7% in 2004.
Similarly, 19% received muromonab-CD3 in 1995 versus
only 4% in 2004. Practice patterns have changed with
the clinical availability of new agents, and with concerns
regarding perceived increased risks of vascular rejection
(secondary to human anti-murine antibody development),
cytomegalovirus infection, and lymphoproliferative dis-
ease. The use of antithymocyte globulin (rabbit) in heart
transplantation increased from 0% in 1998 to 16% in 2004.
Similarly, the use of the anti-IL-2 receptor antibodies, da-
clizumab and basiliximab, increased from 0% in 1997 to
26% (15.4% for daclizumab, 10.3% for basiliximab) in
2004. Alemtuzumab was used for 2% of heart recipients
in 2004, the first year its use has been reported.
In the cohort of patients transplanted between 2000
and 2004, the three most commonly used mainte-
nance regimens at the time of discharge were cy-
closporine/mycophenolate mofetil (47% of patients receiv-
ing induction), tacrolimus/mycophenolate mofetil (24%)
and cyclosporine/azathioprine (9%).
Maintenance immunosuppression before
discharge for heart transplantation
Figure 22 shows the trends over the past 10 years in main-
tenance immunosuppressive therapy prior to discharge.
Cyclosporine-based regimens have decreased steadily
from 87% in 1995 to 51% in 2004 (66% of which is with
Neoral and 28% is with Gengraf). Conversely, the use of
tacrolimus-based regimens has increased from 4% in 1995
to 47% in 2004. Since the introduction of generic formu-
lations of cyclosporine in 2000, their administration has
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Figure 22: Trends in maintenance immunosuppression prior





















Source: 2005 OPTN/SRTR Annual Report, Table 11.6d.
Figure 23: Trends in discharge immunosuppression regimens
for heart transplantation, 1995–2004.
steadily increased from 2% of the total cyclosporine use to
29% in 2004. Prescription of azathioprine has had a steady
decrease from 87% in 1995 to 9% in 2004, while utilization
of mycophenolate mofetil has increased, rising from 3% in
1995 to 85% in 2004. Sirolimus usage prior to discharge
peaked at 10% in 2002 and dropped to 5% in 2004. While
corticosteroids are still used for the majority of patients,
there has been a slight downward trend from a high of
97% in 2001 to 92% in 2004.
At the time of discharge, the most common regi-
mens are cyclosporine/mycophenolate mofetil in 41% and
tacrolimus/mycophenolate mofetil in 39%, the latter be-
ing the fastest-growing regimen over the past decade
(Figure 23). Both of these regimens are used with
concomitant steroids 95% of the time. The use of a
tacrolimus/sirolimus regimen peaked at 6% in 2002, at
the time of an ongoing multi-center clinical trial, and
has declined to only 1% of the patients in 2004. Cy-
closporine/azathioprine, which was by far the most com-
mon regimen through the 1980s and mid-1990s, is now


















Source: 2005 OPTN/SRTR Annual Report, Table 11.6f.
Figure 24: Trends in immunosuppression maintenance regi-
mens, 1 year posttransplant for heart transplantation, 1999–
2003.
were not on any calcineurin inhibitor at the time of dis-
charge, being maintained only on sirolimus/mycophenolate
mofetil—and, presumably, steroids.
Maintenance immunosuppression 1 and 2 years
following heart transplantation
In the most recent cohort (2003), by 1 year after trans-
plantation, use of tacrolimus-based regimens increased
to 50% while that of cyclosporine-based regimens de-
creased to 43% (Figure 24). Of these tacrolimus-based
regimens, tacrolimus/mycophenolate mofetil remains the
most commonly prescribed, at 36%. This represents the
first time that tacrolimus-based regimens were employed
more frequently than the regimens based on cyclosporine.
Sirolimus as part of the regimen was used for 11% of pa-
tients at 1 year following transplantation in the 2003 cohort.
At 2 years following transplantation the most com-
mon maintenance regimens are mycophenolate mofetil
combined with cyclosporine or tacrolimus (36% and
31%, respectively). Tacrolimus combined with rapamycin
is the third most common regimen, used for 6% of
the patients. A calcineurin inhibitor-free regimen us-
ing sirolimus/mycophenolate mofetil was used at 2-year
follow-up for 0.1% of the patients transplanted in 2002.
Maintenance regimen change and discontinuation
for heart transplantation
An interesting analysis performed for this report looked at
the percentage of patients on the same regimen at dis-
charge over 3 years following transplantation, for a cohort
of patients who received transplants from 1999 to 2003.
Not surprisingly, the greatest change occurs during the first
year, presumably in response to the occurrence of rejec-
tion, infection and drug side effects. Ongoing ‘regimen at-
trition’ occurs during subsequent years. Figure 25 shows
the changes over time for the four regimens most com-
monly used at discharge.
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Source: 2005 OPTN/SRTR Annual Report, Table 11.6h.
Figure 25: Percentage of heart transplant patients still on dis-
charge regimens at 1, 2 and 3 years posttransplant, for the
four most common regimens in 2001.
For the most commonly used regimens, the highest rate
of conservation of the original discharge prescription was
seen in the tacrolimus/mycophenolate mofetil group with
49–56% of patients still receiving it 3 years after transplan-
tation. For the cyclosporine/mycophenolate mofetil group,
47–51% were still receiving it 3 years after transplanta-
tion. The highest rate of regimen change occurred in the
cyclosporine/azathioprine group, of which only 21% were
still receiving it at 3 years.
Steroid withdrawal and steroid avoidance
for heart transplantation
In the 2004 year cohort, a total of 139 patients had avoided
corticosteroids at discharge, representing 8% of those re-
ceiving heart transplants. Despite the small numbers in-
volved, this represents a relatively large (nearly threefold)
increase in this practice, a rise from only 3% of patients in
2001. Of this steroid avoidance group, the most common
maintenance regimens were tacrolimus/mycophenolate
mofetil and cyclosporine/mycophenolate mofetil (38% and
42% of those undergoing steroid avoidance, respectively).
An analysis of steroid avoidance based on the use of induc-
tion therapy in all patients in the 2000–2004 cohort showed
that 5% of the patients had avoided steroids at the time
of discharge. Of this group, 44% had not received any in-
duction therapy. Of the 56% that had received induction
therapy, the most commonly used induction agent was an-
tithymocyte globulin (rabbit), representing 46% of those re-
ceiving induction and 26% of the entire steroid-avoidance
group.
Analyses, presented in Figure 26, evaluated the steroid-
withdrawal rates at 1 and 2 years following transplan-
tation, based on the original maintenance regimen at
the time of discharge. In 2003, 26% of those patients
receiving steroids at the time of discharge were com-
pletely removed from steroids 1 year later—the highest
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Source: 2005 OPTN/SRTR Annual Report, Table 15.6.2 and 15.6.3.
Figure 26: Steroid-withdrawal rates at 1 and 2 years post-
transplant for heart transplants, 1999–2003.
maintenance regimen associated with steroid withdrawal
was cyclosporine/mycophenolate mofetil, used for 46%
of the total steroid-withdrawal group; 23% of the entire
cyclosporine/mycophenolate mofetil group was removed
from steroids by 1 year. The second most common dis-
charge maintenance regimen associated with steroid with-
drawal was tacrolimus/mycophenolate mofetil, used for 30
of the total steroid-withdrawal group; 27% of the entire
tacrolimus/mycophenolate mofetil group was steroid-free
at 1 year following transplantation.
Similar trends were seen when evaluating steroid-
withdrawal rates at 2 years following transplantation.
For the cohort of patients who received heart trans-
plants in 2002, 35% had steroids withdrawn by 2
years (up from 26% at 1 year). The cyclosporine/
mycophenolate mofetil group made up 45% of the en-
tire steroid-withdrawal group; 34% of this subgroup under-
went steroid withdrawal. The tacrolimus/mycophenolate
mofetil group made up 23% of the entire steroid with-
drawal group, with a 34% rate of steroid withdrawal within
the tacrolimus/mycophenolate mofetil group.
Antirejection treatment for heart transplantation
Despite fluctuations over the past decade, there has been
an overall trend toward less use of all types of antirejec-
tion therapy. In 2003, 654 patients of a total cohort of 2057
received antirejection therapy (32%, down from a 10-year
high of 42% in 1998). The incidence of rejection in the first
year after transplant over the past 10 years has decreased.
This trend may reflect a true decrease in acute rejection
rates associated with the more modern maintenance reg-
imens. Another factor contributing to this decline may be
that more rejection episodes are being treated with only a
change in maintenance agents, resulting in the possibility
that decreased rates of rejection may represent an under-
reporting of rejection episodes as measured by the use of
antirejection therapy.












































Source: 2005 OPTN/SRTR Annual Report, Table 11.6i.
Figure 27: Trends in antibody therapy for rejection episodes
in first year following heart transplantation, 1994–2003.
The great majority of patients (92%) with reported
antirejection therapy received corticosteroids. Eighteen
percent received an antilymphocyte antibody preparation,
the most common being antithymocyte globulin (rabbit)
for 40% of that group, followed by antithymocyte globulin
(equine) for 25% and muromonab-CD3 for 22%. Of inter-
est, 18% of the antibody-treated group received an anti-IL-
2 receptor antibody, despite a lack of data supporting the
use of this class for the treatment of rejection. Figure 27
shows the distribution over the past 10 years of antilym-





The use and types of an induction regimen for lung trans-
plant recipients evolved over the last decade. Figure 28
shows the changing patterns for induction therapy from
1995 through 2004. The use of induction therapy has in-
creased from 22% in 1997 to 50% in 2004, the highest
rate in 10 years. Administration of antithymocyte globulin
(equine), the most commonly used perioperative induction
agent from 1995 to 1999, steadily decreased from 23% in
1995 to 5% in 2004. The most rapid growth has been seen
with the anti-IL-2 receptor antibody class, increasing from
0% in 1997 to 38% in 2004 (23% for basiliximab, 15% for
daclizumab). Basiliximab is currently the most commonly
used induction agent in lung transplantation, accounting
for 46% of all induction therapy used. The use of antithy-
mocyte globulin (rabbit) decreased from a high of 8% in
2002 to 4% in 2004, and muromonab-CD3 is essentially
no longer used (0.5% in 2004). Alemtuzumab was first re-
ported in 2003 for 0.9% of recipients and its prescription
increased to 3% in 2004.
Among the cohort of patients transplanted between
2000 and 2004, for the four most commonly used

















Source: 2005 OPTN/SRTR Annual Report, Table 12.6a.
Figure 28: Trends in induction immunosuppression for lung
transplantation, 1995–2004.
duction regimen was utilized for 38% of patients on
cyclosporine/mycophenolate mofetil, 52% of patients
on tacrolimus/mycophenolate mofetil, 52% of patients
on tacrolimus/azathioprine and 40% of patients on cy-
closporine/azathioprine.
Maintenance immunosuppression before
discharge for lung transplantation
The use of cyclosporine-based regimens for maintenance
therapy before discharge has decreased steadily from 77%
in 1995 to 30% in 2004; 69% of cyclosporine therapy is
with Neoral. Conversely, prescription of tacrolimus-based
regimens increased over the same period, from 9% in
1995 to 70% in 2004 (Figure 29). Similarly, azathioprine
therapy has had a steady decline from 88% in 1995 to
44% in 2004, while mycophenolate mofetil administration
increased from 3% in 1995 to 46% in 2004. Sirolimus
use before discharge peaked at 4% in 2001, but it de-
creased to only 1% in 2004, in response to safety is-
sues associated with impairment of bronchial anastomotic
healing. Corticosteroids are still used for the majority of
patients (97% in 2004), as they have been for the last
10 years.
At the time of discharge, the most common regimens
are tacrolimus/mycophenolate mofetil (the fastest grow-
ing regimen over the past decade), used for 36% of
recipients; tacrolimus/azathioprine (25.1%); cyclosporine/
azathioprine (16.4%), which was the most common
regimen through the 1980s and mid-1990s); and cy-
closporine/mycophenolate mofetil (10.1%). Calcineurin
inhibitor-free regimens are essentially not used at the time
of discharge.
Maintenance immunosuppression 1 and 2 years
following lung transplantation
In the most recent cohort (those who received trans-
plants in 2003), by 1 year following transplantation
the use of tacrolimus-based regimens increased to
71% while the use of cyclosporine-based regimens
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Figure 29: Trends in maintenance
immunosuppression prior to dis-
charge for lung transplantation,
1995–2004.
decreased to 21%. Of these tacrolimus-based regi-
mens, tacrolimus/mycophenolate mofetil remains the
most commonly employed (35%), followed by tacrolimus/
azathioprine (23%). Sirolimus was used as part of a regi-
men for only 5% of patients at 1 year following transplan-
tation.
At 2 years following transplantation (for those who re-
ceived transplants in 2002), the most common mainte-
nance regimens are tacrolimus combined with mycophe-
nolate mofetil (33%) or azathioprine (22%). Cyclosporine
is only administered in 21% of the regimens.
Maintenance regimen change and discontinuation
for lung transplantation
An interesting analysis performed for this report examined
the percentage of patients remaining on the same regi-
men at discharge over 3 years following transplant. The
greatest changes occurred during the first year, presum-
ably in response to the occurrence of rejection, infection
and drug side effects. However, regimens continued to be
modified after the first year, reflecting persistent long-term
problems following lung transplantation, including the high
incidence of late infections and chronic rejection. Figure 30
shows the changes over time for the four regimens most
frequently administered at discharge.
For the most commonly used regimens, the rate
of conservation of the original discharge regimen in
the 2002 tacrolimus/mycophenolate mofetil group was
only 54% at 3 years following transplantation (yet it
was the highest for all the regimens). For the 2001
tacrolimus/azathioprine group it was only 33%, and for
the 2002 cyclosporine/mycophenolate mofetil group it was
only 16%. The highest rate of regimen change occurred in
the cyclosporine/azathioprine group, of which only 12%
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Source: 2005 OPTN/SRTR Annual Report, Table 12.6h.
Figure 30: Percentage of lung transplant patients still on orig-
inal discharge regimens at 1, 2 and 3 years posttransplant, for
the four most common regimens in 2001.
Steroid withdrawal and steroid avoidance
for lung transplantation
In the 2004 cohort, only 31 patients had avoided corti-
costeroids at discharge, representing 3% of all those re-
ceiving lung transplants. This represents a stable steroid-
avoidance rate over the past 10 years (SRTR analysis, May
2005).
When analyzing the rate of steroid avoidance based on the
use of induction therapy in all patients who received lung
transplants between 2000 and 2004 cohort, 3% of the pa-
tients had avoided steroids at the time of discharge, 54%
of whom had not received any induction therapy. Among
those that did receive induction therapy, the most com-
monly used induction agent was an anti-IL-2 receptor anti-
body agent, representing 67% of those receiving induction
and 31% of the entire steroid-avoidance group.
An analysis of the steroid-withdrawal rate at 1 year fol-
lowing transplantation, based on the original maintenance
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regimen at the time of discharge demonstrated that in
2003, only 2% of those patients on steroids at the time
of discharge were completely off them 1 year later, repre-
senting the lowest rate among any solid-organ transplants.
There has been no change in this rate over the past 5 years.
Furthermore, a backward trend was seen when evaluat-
ing steroid-withdrawal rates at 2 years posttransplant. Only
2% of the 2002 patient cohort had steroids withdrawn by
2 years—down from 4% at 1 year in the same 2002 group,
indicating a small net increase in the rate of steroid use
(SRTR analysis, May 2005).
Antirejection treatment for lung transplantation
Over the past decade there has been a small trend to-
ward less use of all types of antirejection therapy. In 2003,
354 patients of a total cohort of 1099 received antirejec-
tion therapy (32%, down from a 10-year high of 53% in
1995). The incidence of rejection in the first year after
transplant over the past 10 years has dropped. While this
drop may indeed result from a decrease in acute rejec-
tion rates associated with the more modern maintenance
regimens, there are other possible explanations as well.
First, it is possible that more rejection episodes are be-
ing treated with only a change in the maintenance agents,
which could lead to underreporting of rejection episodes
as measured by the use of antirejection therapy. Second, a
change in practice patterns toward fewer surveillance biop-
sies in many lung transplant programs may yield a lower
detection rate and thus a falsely low reported rejection rate.
The great majority of patients (96%) requiring antirejec-
tion therapy received corticosteroids. In the 2003 cohort,
16% received an antilymphocyte antibody preparation. Sur-
prisingly, the most common agent used was daclizumab
(43%), despite a lack of data supporting the use of this
class of agents in treating rejection. Figure 31 shows the
distribution of antilymphocyte antibody use for the treat-





















Source: 2005 OPTN/SRTR Annual Report, Table 12.6i.
Figure 31: Trends in antibody therapy for rejection episodes
in first year following lung transplantation, 1994–2003.
Heart-Lung Transplantation
With only 39 heart-lung transplants performed in 2004, it is
difficult to make any definitive statements regarding chang-
ing patterns in immunosuppressive agent use. As a gen-
eral observation, the changes in immunosuppression that
have occurred in heart-lung transplantation seem to reflect
changes that have occurred in isolated lung transplanta-
tion more than those seen in isolated heart transplantation.
Since this type of transplant is performed at so few centers,
it is likely that patterns in immunosuppressive agent use
are more related to protocol changes at the small subgroup




During the past decade, the use of induction therapy was
at a low of 24% in 1998 and at a high of 73% in 2001,
with a rate of 60% in 2004. Use of antithymocyte globulin
(equine), the most commonly used perioperative induction
agent from 1995 through 2000, decreased from 44% in
1995 to 14% in 2004. The most rapid growth has been seen
with the anti-IL-2 receptor antibody class—increasing from
0% in 1998 to 30% in 2004 (19% for daclizumab, 11% for
basiliximab). Daclizumab is currently the most commonly
used induction agent in heart-lung transplantation, account-
ing for 32% of all induction therapy. The administration of
antithymocyte globulin (rabbit) has also increased and rep-
resented 23% of antibody induction prescribed in 2004.
Alemtuzumab was first reported in 2004; it was used for
5% of the patients.
In the cohort of patients transplanted between 2000 and
2004, for the four most commonly used maintenance reg-
imens at the time of discharge, an induction regimen was
used for 72% of patients on cyclosporine/mycophenolate
mofetil, 52% of patients on tacrolimus/mycophenolate
mofetil, 75% of patients on tacrolimus/azathioprine and
71% of patients on cyclosporine/azathioprine.
Maintenance immunosuppression before
discharge for heart-lung transplantation
Over the past 10 years, use of cyclosporine-based regi-
mens for maintenance therapy before discharge decreased
from 76% in 1995 to 38% in 2004. Conversely, tacrolimus-
based regimens steadily increased over the same period,
from 14% in 1995 to 65% in 2004. Similarly, the use of
azathioprine decreased from 95% in 1995 to 32% in 2004,
while mycophenolate mofetil administration increased, ris-
ing from 0% in 1995 to 50% in 2004. Sirolimus use before
discharge was at its highest in 2003 (6%), the first year
it appeared; its use has decreased in response to safety
issues associated with impairment of airway anastomotic
healing, dropping to only 3% in 2004. Corticosteroids were
used for 100% of the patients in 2004.
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At the time of discharge, 32% of patients received
tacrolimus/mycophenolate mofetil, the most common reg-
imen and the only one whose use has increased over the
past decade. Cyclosporine/azathioprine, the most common
regimen from the 1980s through the mid-1990s, was em-
ployed for only 15% of patients in 2004. No use of cal-
cineurin inhibitor-free regimens at the time of discharge
has been reported.
Maintenance immunosuppression 1 and 2 years
following heart-lung transplantation
In the most recent cohort (those who received a heart-
lung transplant in 2003), by 1 year following trans-
plantation, the use of tacrolimus-based regimens in-
creased to 77% while cyclosporine-based regimens de-
creased to 23%. Of these tacrolimus-based regimens,
tacrolimus/mycophenolate mofetil remains the most com-
monly used (36%), followed by tacrolimus/azathioprine
(23%). At 2 years following transplantation, the various
drug combination regimens are all represented.
Due to small numbers of patients for the 1999–2003 cohort
in each immunosuppressive combination, it is not possible
to comment on trends in regimen changes 3 years after
transplantation.
Steroid withdrawal and steroid avoidance
for heart-lung transplantation
Neither steroid avoidance nor steroid withdrawal has been
performed in the most recent cohorts of heart-lung trans-
plants (SRTR analysis, May 2005).
Antirejection treatment for heart-lung transplantation
Data are available on only eight heart-lung transplant re-
cipients with reported rejection in 2003. Sixty-two percent
received corticosteroids and 12% received antithymocyte
globulin (equine).
Comparisons Between Organs
Over the past decade, the use of induction therapy in
solid-organ transplantation has increased for all organs ex-
cept for combined heart-lung transplants. Increases have
ranged from modest to dramatic. In 2003 and 2004, induc-
tion immunosuppression was most commonly employed
for pancreas (PTA 81%, SPK 80% and PAK 80%) and
kidney (72%) transplant recipients, and least commonly
for liver transplant recipients (20%). In addition, induc-
tion strategies were used for roughly half of all heart-lung
(60%), lung (50%), intestine (50%) and heart (47%) recip-
ients (Figure 32). Polyclonal antibody induction with an-
tithymocyte globulin of equine or antithymocyte globulin
of rabbit is the most frequent choice for kidney and pan-
creas transplantation. Anti-IL-2 receptor antibody induction
with basiliximab or daclizumab is more common for liver,
heart-lung, lung and heart transplantation. Alemtuzumab
















PTA: Pancreas Transplant Alone. PAK: Pancreas After Kidney. 
SPK: Simultaneous Pancreas-Kidney. Source: 2005 OPTN/SRTR 
Annual Report, Table 1.9.
Figure 32: Comparative use of induction immunosuppression
















Tacrolimus Maintenance Cyclosporine Maintenance
PTA: Pancreas Transplant Alone. PAK: Pancreas After Kidney. SPK:
Simultaneous Pancreas-Kidney. Source: 2005 OPTN/SRTR Annual Report, 
Table 1.9.
Figure 33: Comparative calcineurin inhibitor use for immuno-
suppression prior to discharge, by organ, 2004.
of PTA, 19% of SPK and PAK and 19% of intestine trans-
plant induction. It is now the most common agent used for
induction in intestine transplantation.
With the exception of those who received a solitary pan-
creas transplant (PTA 76% and PAK 88%), calcineurin in-
hibitors are prescribed for 90% or more for all categories
of solid-organ recipients at discharge from the initial trans-
plant hospitalization (Figure 33). Except in the instance of
heart transplantation (47%), 65% or more of all solid-organ
transplant recipients receive tacrolimus. The changes in
calcineurin inhibitor since 1995 are summarized in Table
2. At discharge, antimetabolite usage varies from a low of
9% for intestine recipients to a high of 95% for heart re-
cipients. The use of mycophenolate mofetil predominates,
with fewer than 3% of recipients receiving azathioprine
in all abdominal organ transplantation. In contrast, azathio-
prine is prescribed for 9% of heart, 44% of lung, and 32%
of heart-lung recipients. Sirolimus use is uncommon (<6%)
in lung, heart-lung, heart and liver transplantation, but has
gained more acceptance for SPK (17%), PAK (16%), PTA
(12%), kidney (12%) and intestine (12%) recipients.
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Table 2: Calcineurin inhibitor use for immunosuppression before
discharge, by organ, 1995 vs. 2004
Tacrolimus Cyclosporine
Organ 1995 2004 1995 2004
Kidney 6.7% 72.1% 81.7% 21.1%
PTA 58.3% 74.2% 36.1% 1.3%
PAK 53.3% 79.6% 36.7% 8.6%
SPK 36.6% 84.3% 58.2% 6.4%
Liver 47.5% 88.8% 47.1% 8.0%
Intestine 93.5% 97.6% 6.5% 0.0%
Heart 4.3% 47.1% 86.7% 51.3%
Lung 9.1% 69.8% 77.0% 29.7%
Heart-lung 13.6% 64.7% 76.3% 38.2%
PTA, pancreas transplant alone; PAK, pancreas after kidney; SPK,
simultaneous pancreas-kidney.
Source: 2005 OPTN/SRTR Annual Report, Tables 5.6e, 6.6e, 7.6e,
8.6e, 9.6e, 10.6e, 11.6e, 12.6e and 13.6e.
At the end of the first year following transplantation, 83%
or more of all solid-organ recipients receive a calcineurin in-
hibitor. Tacrolimus is the predominant calcineurin inhibitor
employed for maintenance immunosuppression of all cat-
egories of solid organs. Except in the cases of PTA (53%),
liver (37%) and intestine (7%), 75% or more of solid-organ
maintenance immunosuppression regimens include an an-
timetabolite. Again, only among recipients of thoracic or-
gans is azathioprine use seen for more than 2% of pa-
tients. The use of sirolimus generally increases during the
first year. By the end of the first year, it is employed for
23% of SPK, 23% of PAK, 21% of PTA, 18% of kidney,
15% of heart, 10% of liver, 9% of lung and 8% of intes-
tine recipients. During the first posttransplant year, the use
of sirolimus increases for all but heart-lung and intestine
transplant recipients.
Steroid avoidance is an emerging trend in solid-organ trans-
plantation. In 2004, 48% of PTA, 28% of living donor kid-
ney, 27% of intestine, 24% of SPK, 22% of living donor
liver, 20% of deceased donor kidney, 20% of deceased
donor liver, 8% of heart, 4% of living donor lung and 3%
of deceased donor lung transplant recipients were not pre-
scribed corticosteroids at discharge form their initial trans-
plant hospitalization, as seen in Figure 34 (SRTR analysis,
May 2005). By the end of the second posttransplant year,
the steroid-withdrawal rate decreased for all but deceased
donor liver (66%), living donor liver (63%), heart (35%) and
living donor lung (8%).
Despite the growing application of steroid avoidance and
withdrawal as seen in Figures 34 and 35, ‘triple immuno-
suppression’ with a calcineurin inhibitor, corticosteroid and
either an antimetabolite or a TOR inhibitor predominates
at discharge and at 2 years following transplantation for
those transplanted between 1995 and 2004, and between
1998 and 2002, respectively. Except for the discipline of

































Source: 2005 OPTN/SRTR Annual Report, Tables 15.4a, 15.5a,15.6, and 
SRTR analysis.  

































Source: 2005 OPTN/SRTR Annual Report, Tables 15.4a, 15.5a,15.6, and 
SRTR analysis.  
Figure 35: Steroid-withdrawal rates at 1 year posttransplant
for all deceased donor transplants, 2003.
tacrolimus monotherapy (23% at discharge and 22% at
2 years), tacrolimus plus corticosteroids (56% at discharge
and 42% at 2 years) and tacrolimus plus sirolimus and
corticosteroids (7% at discharge and 20% at 2 years) are
common, the most frequently employed immunosuppres-
sive regimen is the combination of tacrolimus, mycophe-
nolate mofetil and corticosteroids. Only in the case of heart
transplantation does the prescription of the combination of
cyclosporine, mycophenolate mofetil and corticosteroids
(39 % at discharge and 28% at 2 years), exceed that
of tacrolimus, mycophenolate mofetil and corticosteroids
(36% at discharge and 24% at 2 years).
Among those transplanted in 2003 and treated for rejection
during the first posttransplant year, corticosteroids were
administered to 62–96% of recipients (heart-lung and lung,
respectively). Antibody use varied from 12% (heart-lung)
to 77% (PTA). The administration of alemtuzumab as ther-
apy for rejection is rising especially in intestine (15%), PAK
(28%) and PTA (42%) transplantation.
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As the number of available choices expands, the mosaic of
the practice of immunosuppression in transplantation be-
comes more textured. New protocols emerge and displace
previous behaviors. This article reviews and describes a
number of these trends, including the increased application
of corticosteroid avoidance and withdrawal, the evolution
toward tacrolimus-centered immunosuppression, and the
emerging use of alemtuzumab.
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